Annexon announces completion of enrollment in pivotal phase 3 archer ii trial of vonaprument (formerly anx007) for dry age-related macular degeneration (amd) with geographic atrophy

Expedited enrollment surpassing 630 targeted participants underscores the strong demand for a therapy focused on vision preservation
AMD Ratings Summary
AMD Quant Ranking